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Abstract. The Janus tyrosine kinases (JAKs) have shown great promise as 
therapeutic protein targets in the treatment of cancer and inflammation diseases. 
This study used pharmacophore modeling to identify potential inhibitors of Janus 
kinase 3 (JAK3). A pharmacophore model was developed based on a known 
JAK3 inhibitor (1NX) and was employed to search for potential JAK3 inhibitors 
against Indonesian herbal compounds. Among 28 hit molecules that were 
identified and subjected to a molecular docking protocol against JAK3, the three 
compounds that had the highest affinities toward JAK3 were camelliaside B, 3-
O-galloylepicatechin-(4beta-6)-epicatechin-3-O-gallate, and mesuaferrone B. 
These were then each subjected to a 50-ns molecular dynamics (MD) simulation. 
Analysis of RMSD and RMSF values indicated that the three compounds 
reached stability during the MD simulation. Interestingly, all three compounds 
had lower binding energies than 1NX against JAK3, as predicted by the MM-
PBSA binding energy calculation. 
Keywords: Janus kinase; MM-PBSA; molecular dynamics simulation; pharmacophore 
modeling; virtual screening. 
1 Introduction 
Janus kinases (JAKs) are members of the family of intracellular tyrosine 
kinases. They are phosphotransferases that bind to cytokine receptors, including 
interleukins, interferons, and many other cytokines [1]. Janus kinases, along 
with their signal transducer and activators of transcription proteins (STAT), 
mediate transduction of signaling cascades through the JAK-STAT-PI3K-
MAPK pathway, which is crucial for the differentiation, proliferation and 
survival of a variety of cell types [2-5].  
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The JAK family consists of 4 isoforms, namely JAK1, JAK2, JAK3 and Tyk2. 
They have similar biochemical properties due to high sequence homologies. 
While JAK1, JAK2, and Tyk2 are predominantly found in a variety of cell 
types, JAK3 is chiefly expressed in hematopoietic, myeloid and lymphoid cells 
[6]. More specifically, JAK3 is limited to the gamma chain (γc) subfamily of 
cytokines in both humans and mice [3,4,7,8]. Thus, inhibition of JAK3 is a 
promising approach for the elimination of autoimmune and inflammatory 
diseases [9]. Various JAK3 inhibitors have been researched, including 
tofacitinib and ruxolitinib [8,9]. However, several adverse effects, including 
increased risk of infection, lymphoma, cancer and tuberculosis, were noted in 
the clinical use of these inhibitors, which are attributable to the inhibition of 
multiple JAKs due to the high extent of structural conservation of the ATP 
binding site of JAK [1,3,4,10,11]. Thus, the search for more selective and 
potent JAK3 inhibitors is being actively pursued, both in academic institutions 
and pharmaceutical companies. Here we report a pharmacophore model of 
JAK3, which was used to screen the Indonesian Medicinal Plants Database 
(HerbalDB) [12]. Pharmacophore-based in silico screening was combined with 
a molecular docking simulation to identify novel potential JAK3 inhibitors from 
the Indonesian herbal database. Further, a molecular dynamics simulation was 
performed to confirm the stable interaction between the ligands and JAK3. 
Finally, the Molecular-Mechanics Poisson Boltzmann Surface Area (MM-
PBSA) method was utilized to assess the affinity of the hit molecules. 
2 Method  
2.1 Structure-based Pharmacophore Modeling 
A pharmacophore model was built by employing the structure of a carboxamide 
(1NX) complexed with JAK3, which was retrieved from Research 
Collaboratory for Structural Bioinformatics PDB ID 3ZEP [13]. Validation of 
the pharmacophore model was conducted by performing screening against 100 
actives taken from BindingDB [14] and 7500 decoys retrieved from the DUD-E 
database [15]. This task was completed by using the LigandScout Advanced 4.3 
software [16]. The validated model was employed to identify potential 
inhibitors of JAK3 against the Indonesian Medicinal Plants Database 
(HerbalDB) [12], which contains 1379 molecules.  
2.2 Molecular Docking, Molecular Dynamics and MM-PBSA 
Energy Calculation 
The obtained hit molecules from pharmacophore screening were then subjected 
to molecular docking simulation to the JAK3 protein. A set of polar hydrogens 
was added and Kollman charges were assigned to the JAK3 in the receptor 
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preparation step. This task was performed using AutoDockTools 1.5.6. Each 
ligand was then docked into an active site of JAK3, which was established 
based on the grid box, which was the center of the native ligand (1NX) 
coordinates. The molecular docking was carried out by using the iDock 
software [17]. Each docked ligand conformation was analyzed and visualized 
using Discovery Studio Visualizer 2016 and the three molecules with the best 
binding affinities and with good interaction were subjected to a molecular 
dynamics simulation.   
The molecular dynamics simulation was performed for each four ligands 
complexed with JAK3 employing the AMBER16 package [18-21]. The leap 
module was used to prepare each complex using the ff14SB force field [22] for 
the protein and the GAFF force field [23], and AM1-BCC [24] for the ligands. 
The protein was protonated according to the default Amber procedure. The 
minimization, heating and equilibration steps, the MM-PBSA calculation and 
the parameters employed are described in our previous publication [21]. The 
production MD simulation was conducted for 50 ns in NPT ensemble [21]. 
3 Results and Discussion 
The structure of a carboxamide (1NX) complexed with JAK3 was adopted for 
building the pharmacophore model, which resulted in several pharmacophore 
models. From these models, one hypothesis was found, consisting of one 
hydrogen bond (H-bond) acceptor, two H-bond donors, and two hydrophobic 
features. Figure 1 shows the generated pharmacophore model. 
 
Figure 1 3D pharmacophore model, consisting of one H-bond acceptor (red 
dotted lines), two H-bond donors (green dotted lines), and two hydrophobic 
(yellow sphere) features. 
The pharmacophore model was then validated against 100 actives and 7500 
decoys. It was found that the area under curve (AUC) of the receiver operating 
characteristic (ROC) curve was 0.52. Meanwhile the calculation of the goodness 
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of hit score (GH score) gave a result of 0.76. Both parameters indicated the 
validity of the pharmacophore model developed. Figure 2 displays the AUC of 
the ROC curve.   
 
Figure 2 The AUC plot of the ROC curve. 
Screening for hit molecules against the Indonesian Herbal Database (HerbalDB) 
yielded 28 hit molecules. Molecular docking of each hit molecule into JAK3 
gave binding energies between −7.52 and −9.97 kcal/mol. These energy values 
are comparable to the binding energy of a docked native ligand (1NX) of −8.82 
kcal/mol. Further, we selected the three best docked hit molecules for an MD 
simulation, i.e. camelliaside B/Lig2 (E = −9.97 kcal/mol), 3-O-
galloylepicatechin-(4beta-6)-epicatechin-3-O-gallate/lig 10 (E = −9.91 
kcal/mol), and mesuaferrone B/Lig17 (E = −9.74 kcal/mol). Figure 3 shows the 
hit structures of the three best docked hit molecules. 
 
Figure 3 The hit structures of the three best docked hit molecules. 
Binding conformations of the hit molecules occurred in the binding site of 
JAK3. Lig2 formed five H-bond interactions with Lys830, Cys909, Arg911, 
Asp967, and Arg953, while Lig10 formed H-bond interactions with Lys855, 
Leu905, Glu903, Lys830, Asp912, Met902, and Gln827. The binding of Lig17 
was also corroborated with H-bonds Cys909, Asp967, and Leu905. Amino acid 
residue Cys909 is known as a key active site residue of JAK3. Figure 4 depicts 
the binding interactions of each ligand within the binding pocket of JAK3. 
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Figure 4 The binding interactions of Lig2, Lig10 and Lig17 within the binding 
pocket of JAK3. 
3.1 Molecular Dynamics Simulations  
As the molecular docking method does not consider the physiological condition 
for stable interaction of the hit molecules, each three best docked hit molecules 
complexed with JAK3 were subjected to an MD simulation. The MD simulation 
was carried out for 50 ns to see whether the ligands would retain interaction 
with JAK3. The values of root mean square deviation (RMSD) during the MD 
simulation run were used to monitor the stability of the complex. Figure 5 
shows the RMSD values of the heavy atoms (Cα, C, N, O) of JAK3.  
 
Figure 5 The RMSD values of the main protein atoms of each JAK3 ligand 
system during 50 ns MD accounted for Lig2, Lig10, Lig17, and 1NX, colored 
red, green, blue, and purple, respectively. 
It is noted that each ligand maintained stable interaction with JAK3. Lig10 
(green) and Lig17 (blue) had lower RMSD values than 1NX, which indicates 
more stable interactions. All fluctuations of the RMSD values for all ligands 
were under 3 Å, which can be considered stable conformational changes, during 
50 ns.  
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The fluctuation of the individual amino acid residues during the MD simulation 
was recorded as a root mean square fluctuation (RMSF) plot. Figure 6 displays 
the RMSF values for the individual amino acids during 50 ns.   
 
Figure 6 Plot of RMSF for Lig2, Lig10, Lig17 and 1NX, colored red, green, 
blue, and purple, respectively. 
The same pattern of amino acid fluctuation was noted in the whole region of 
JAK3, which indicates the same binding interaction of the ligands. Overall, the 
amino acid residues fluctuated under 3 Å, except for those composing the 
carboxy and amino ends of the protein, which indicates stable dynamics during 
50 ns. Dominant peaks were recorded in the residues of around Asp33 
(Asp846), HisS46 (His859), Ala101 (Ala919), Asp159 (Asp977), which 
corresponds to loop regions. The higher peak at Ser224 (Ser1048) is associated 
with the end of a helix. On the other hand, the amino acid residues involved in 
the H-bond interactions over all ligands, including Cys91 (Cys909), showed 
more rigid fluctuation, which indicates protein stability induced by ligand 
interactions. 
Meanwhile, several H-bond interactions of docked conformations were also 
retained in the MD simulation. For example, H-bonds between Lig2 and JAK3 
occurred with occupancies of 45.73%, 26.81%, 16.04%, and 15.72%, with the 
residues of Arg953 (Arg135), Arg911 (Arg93), Lys830 (Lys17), and Asp967 
(Asp149), respectively. Newly formed H-bond interactions with very high 
occupancies (97.31 and 90.8%) were recorded, namely with Glu871 (Glu58) 
and Glu85 (Glu903), respectively. On the other hand, Lig10 retained H-bond 
interactions with Asp912 (Asp94), Lys830 (Lys17), Glu903 (Glu85), Leu905 
(Leu87), Gln827 (Gln14) and Lys855 (Lys42), with occupancies of 44.89%, 
39.04%, 37.86%, 28.39, 21.54% and 17.36%, respectively. Newly formed H-
bond interactions with very high occupancy (71.04 %) were recorded with 
Glu871 (Glu58) and with moderate occupancy (51.9%) with Arg953 (Arg135). 
The binding of Lig17 maintained H-bond interaction with Asp967 (Asp149) 
with 75.72% occupancy, and novel H-bonds were maintained with Arg953 
282 Muhammad Arba, et al. 
(Arg135) and Asp912 (Asp94) with 88.25% and 54.88% occupancy, 
respectively. Table S1 shows the H-bond occupancies recorded during the 50-ns 
simulation. 
3.2 Free Binding Energy Calculations  
The stable conformation of ligands during the MDs simulation run was then 
subjected to the MM-PBSA protocol for free binding energy prediction. 
Prediction of binding energy using the MM-PBSA method is widely considered 
as more accurate compared to using the docking method. Table 1 shows the 
calculated binding affinities from the MM-PBSA method. Interestingly, the free 
binding energies of Lig2 (ΔEPBTOT = −19.35 ± 7.16), Lig10 (ΔEPBTOT = −26.55 ± 
8.13), and Lig17 (ΔEPBTOT = −25.34 ± 3.94) were more negative than that of 
1NX (−16.90 ± 3.04). The binding energy of Lig17 appeared to be most 
negative among them. Negative binding free energy originating from favorable 
electrostatic, van der Waals as well as non-polar energies contributes to the 
solvation energy.  
Tabel 1 MM-PBSA free binding energy for each ligand. 









1NX −67.65 ± 11.09 −30.53 ± 2.68 85.07 ± 10.94 −3.81 ± 0.20 −16.90 ± 3.04 
Lig2 −59.40 ± 13.19 −49.07 ± 5.09 94.70 ± 8.69 −5.58 ± 0.23 −19.35 ± 7.16 
Lig10 −91.14 ± 11.90 −57.84 ± 5.10 128.89 ± 15.77 −6.46 ± 0.22 −26.55 ± 8.13 
Lig17 −55.88 ± 7.25 −44.37 ± 3.48 79.91 ± 7.20 −5.00 ± 0.13 −25.34 ± 3.94 
4 Conclusion 
Structure-based pharmacophore modelling was performed based on JAK3-1NX 
interaction. A pharmacophore hypothesis was built and validated. It was then 
used to identify hit molecules in the Indonesian Herbal Database. Twenty-eight 
hit molecules were retrieved and then docked into the active site of JAK3 to 
reveal their binding interactions. The hit molecules maintained their interactions 
with the JAK3 through H-bond and hydrophobic interactions. The three best 
hits, i.e. camelliaside B, 3-O-galloylepicatechin-(4beta-6)-epicatechin-3-O-
gallate, and mesuaferrone B, were subjected to an MD simulation, which 
showed good stability during 50 ns. Prediction of binding affinities using the 
MM-PBSA method showed that the three top hit molecules displayed stronger 
affinities than 1NX. The contribution of the van der Waals, electrostatic and 
nonpolar energies to the solvation energy interactions were favorable for most 
of the three molecules. The present work suggests that these three molecules 
may serve as potential inhibitors of JAK3. 
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